It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lesch-Nyhan disease (LND) is an inherited disorder caused by pathogenic variants in the HPRT1 gene, which encodes the purine recycling enzyme hypoxanthine–guanine phosphoribosyltransferase (HGprt). We generated 6 induced pluripotent stem cell (iPSC) lines from 3 individuals with LND, along with 6 control lines from 3 normal individuals. All 12 lines had the characteristics of pluripotent stem cells, as assessed by immunostaining for pluripotency markers, expression of pluripotency genes, and differentiation into the 3 primary germ cell layers. Gene expression profiling with RNAseq demonstrated significant heterogeneity among the lines. Despite this heterogeneity, several anticipated abnormalities were readily detectable across all LND lines, including reduced HPRT1 mRNA. Several unexpected abnormalities were also consistently detectable across the LND lines, including decreases in FAR2P1 and increases in RNF39. Shotgun proteomics also demonstrated several expected abnormalities in the LND lines, such as absence of HGprt protein. The proteomics study also revealed several unexpected abnormalities across the LND lines, including increases in GNAO1 decreases in NSE4A. There was a good but partial correlation between abnormalities revealed by the RNAseq and proteomics methods. Finally, functional studies demonstrated LND lines had no HGprt enzyme activity and resistance to the toxic pro-drug 6-thioguanine. Intracellular purines in the LND lines were normal, but they did not recycle hypoxanthine. These cells provide a novel resource to reveal insights into the relevance of heterogeneity among iPSC lines and applications for modeling LND.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
2 Emory University School of Medicine, Department of Human Genetics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
3 Donders Institute for Brain, Radboud University Medical Center, Department of Neurology, Cognition and Behavior, Nijmegen, The Netherlands (GRID:grid.189967.8); Amphia Hospital, Department of Neurology, Breda, The Netherlands (GRID:grid.413711.1)
4 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University, Neurosciences Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
5 Hôpital Universitaire Necker, Laboratoire de Biochimie Métabolomique Et Protéomique, Paris, France (GRID:grid.412134.1) (ISNI:0000 0004 0593 9113)
6 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University, Neurosciences Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Pharmacology and Chemical Biology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
7 Emory University Rollins School of Public Health, Department of Epidemiology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
8 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Psychiatry & Behavioral Sciences, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Cell Biology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
9 Emory University School of Medicine, Department of Human Genetics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Pediatrics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)
10 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Human Genetics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University, Neurosciences Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Emory University School of Medicine, Department of Pediatrics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502)